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Abstract (199 words) 
Paclitaxel is a good compound for regional (intraperitoneal) chemotherapy of peritoneal 
carcinomatosis. During IPEC, a cytotoxic solution is circulated in the peritoneal cavity, thereby 
promoting close contact between the cytotoxic agent and the exposed (residual) tumour tissue. To 
further explore the role of PTX in this type of treatment and study the impact of treatment 
modalities on tumour tissue penetration, in-vivo animal experiments were set-up.      
In literature, PTX tumour uptake is frequently studied using autoradiography and/or fluorescence 
microscopy techniques. Owing to their semi-quantitative nature on one hand and the difficulty of 
incorporating imaging data within a pharmacokinetic-pharmacodynamic modelling framework on the 
other hand, we set out to develop a validated assay for the quantification of PTX in tumour tissue 
samples. Furthermore, in order to maximize spatial resolution, care was taken to minimize the 
sample weight necessary for the analysis.  
Based on an enzymatic tumour tissue digestion protocol, an easy, less labour-intensive, when 
compared to mechanical tissue disruption techniques, method was developed. Through validation 
experiments we showed that our method reliably quantifies PTX in a working range of 30 – 8000 ng / 
g tumour tissue. Finally, using samples from the in-vivo experiments we demonstrated the suitability 
of the developed method. 
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1 Introduction 
Paclitaxel (PTX), which binds and stabilizes the microtubule, causing cell death, has been used as an 
anticancer agent since 1984. Paclitaxel shows anticancer activity for a variety of human cancers, 
including breast, ovarian and prostate. Its favourable pharmacokinetic properties, e.g. slow 
peritoneal clearance, makes it a good candidate compound for intraperitoneal perioperative 
chemotherapy (IPEC)[1] of peritoneal carcinomatosis (PC). During IPEC, a solution containing a 
cytotoxic agent, e.g. PTX, is instilled into the peritoneal cavity, thereby promoting close contact 
between the cytotoxic agent and the exposed (residual) tumour tissue.      
 Although IPEC as a tool for regional drug delivery has a strong pharmacokinetic 
rationale in the treatment of PC, controversy remains regarding the optimal treatment strategies 
that will optimize efficacy whilst minimizing systemic exposure. Besides the ongoing debate on the 
duration of the perfusion or the optimal carrier solution, questions regarding the extent of tumour 
tissue penetration following IPEC treatment remain[2]. 
PTX penetration has been studied in-vitro as well as in-vivo, using, respectively, cell 
monolayers [3] or multicellular layer cultures [4;5] and human tumour xenografts [6-8]. 
Autoradiography [3;7;8], using 3H-PTX, or fluorescence microscopy [5;6], using fluorescently labelled 
PTX, are used most often. Using these techniques, rather than an accurate determination of the PTX 
concentration in tumour tissue, a relative scale is used to describe penetration as a function of time 
and/or space. Because of the semi-quantitative nature of these imaging techniques, they are 
sometimes combined with a conventional whole tumour homogenization and HPLC analysis [8;9] to 
be able to report accurate PTX concentrations in tissue. However, even in these instances questions 
remain with respect to the performance characteristics of the assay (imprecision/ bias).                
Besides the questions regarding the treatment modalities and the effective penetration of 
PTX in solid tumours, one of the reasons for its limited use is the toxicity (local and systemic) 
associated with IPEC administration of Taxol®. Although necessary for paclitaxel solubility, 
Cremophor EL, the main constituent of Taxol®, has been shown to cause severe adverse effects after 
IPEC administration.[10] As such, despite its wide activity spectrum and its favourable 
pharmacokinetic properties, the use of PTX as a compound for IPEC remains limited. 
Therefore, in support of the development of a new Cremophor EL-free paclitaxel 
formulation, a bioanalytical method to quantify paclitaxel in human tumour xenograft tissue was 
developed. Furthermore, in order to study the effect of carrier solution and treatment modalities on 
PTX tumour penetration, using the tumour harvesting protocol shown in Figure 1, our sample 
pretreatment was optimized to handle low weight tumour tissue samples.  
2 Material and methods 
2.1 Reagents 
Trizma®-base, Sodium dodecyl sulphate (SDS), Proteinase K (from Tritirachium album, 500 units/mL, 
buffered aqueous glycerol solution) and lipase (from porcine pancreas powder) were all from Sigma-
Aldrich (Bornem, Belgium). EDTA, potassium dihydrogen phosphate and di-potassium hydrogen 
phosphate were from VWR® BDH Prolabo® (Leuven, Belgium). 13C6-Paclitaxel (IS) and PTX were from 
Acros Organics (Geel, Belgium) and Chromadex (California, USA), respectively. ULC-grade water and 
methanol were from Biosolve (Valkenswaard, The Netherlands).  
2.2 Buffers and enzyme solutions 
A phosphate buffer (70 mM) in H2O was made by accurately weighing and dissolving 2.0 g 
K2HPO4 and 0.8 g KH2PO4 in 250.0 mL of H2O. Prior to dilution to 250.0 mL, the pH of the buffer was 
adjusted to pH 7.50 by titration with 1 M NaOH. Furthermore, a 50 mM Tris-HCl buffer was made by 
dissolving 0.607 g Trizma®-base into a final volume of 100.0 mL of H2O after adjustment of the pH to 
7.50 with a 1 M HCl solution.  
The final proteinase K solution was made by diluting the buffered aqueous glycerol solution 
(500 units/mL) 100 fold in Tris-HCl buffer to a final concentration of 5 units/mL. Lipase solution (100 
mg/L) was made by dissolving appropriate amounts of lipase in phosphate buffer.      
2.3 Stock solutions, standards and quality control samples 
A stock solution in acetonitrile was prepared for PTX at a concentration of 1.0 mg/mL. This stock 
solution was then further diluted with acetonitrile to obtain working solutions with PTX 
concentrations ranging from 0.016 µg/mL to 4.0 µg/mL. A separate stock solution as well as separate 
working solutions (PTX concentrations 0.04, 0.8 and 3.2 µg/mL, respectively) were prepared for the 
production of the quality control samples. The IS was dissolved in 1 mL acetonitrile and diluted to a 
concentration of 0.80 µg/mL using acetonitrile.    
Blank bovine muscle tissue was spiked with the different working solutions to obtain 
calibrator- / quality control samples. Full details of the preparation of the calibrators and quality 
control samples are given under 2.4.  
2.4 Enzymatic tissue digestion protocol 
Tumour samples and bovine muscle tissue were allowed to thaw at room temperature. Afterwards, 
excised tumour samples were rinsed using a physiological salt solution (9 g/L NaCl in H2O) to remove 
most blood and to rinse off any left-over Taxol® that might have adsorbed to the tumour’s outer 
surface. After further sectioning and exactly weighing of the tumour samples to produce tissue 
specimens weighing 25 mg, tissue specimens were placed in an Eppendorf® vial. 
To this Eppendorf® vial 500 µL lipase-solution, 250 µL proteinase-K solution, 30 µL SDS-
solution (5 mg/100 µL in H2O), 85 µL CaCl2-solution (30 mM in H2O), 50 µL EDTA-solution (100 mM in 
H2O) and 85 µL of Tris-HCl buffer were added. 
For the calibrator samples and the quality control samples, 50 µL of the corresponding 
working solution in acetonitrile was added to the Eppendorf® vial. Concurrently, for the tumour 
tissue samples, 50 µL of blank acetonitrile was added. Final concentrations of the calibrator samples 
ranged from 32 to 8000 ng/g. Quality control samples were prepared at PTX concentrations of 80, 
1600 and 6400 ng/g, respectively.   
Afterwards, the Eppendorf® vials were left to incubate overnight at 55°C whilst continuously 
being shaken (IKA®-Werke GmbH & Co. KG, Staufen, Germany). After at least 16 h of incubation time, 
the Eppendorf® vials were vortex mixed and centrifuged for 10 min. at 3000 xg at 4°C. Following 
centrifugation, samples were stored at 4°C until further handling by solid phase extraction.         
2.4 Solid Phase Extraction procedure 
After centrifugation 50 µL of IS solutions was added to 950 µL of the supernatant. This mixture was 
then loaded onto the SPE cartridges (Oasis® HLC cartridges, Waters, USA) prior to washing of the SPE 
tubes with a sodium hydroxide (pH 10.0) solution and a 70% (v/v) MeOH-solution in H2O. Following 
elution of PTX with MeOH, samples were concentrated by evaporation of the methanol under a mild 
nitrogen stream (30 min, 35°C).  
Finally, samples were reconstituted in 100 µL 50% (v/v) methanol in H2O, transferred to the 
autosampler compartment and kept at 5°C until injection onto the chromatographic system. 
In case of samples above the ULOQ, re-analysis was performed using the supernatant. To this 
end, the supernatant was diluted with a physiological saline solution (20 and/or 400 fold) prior to 
spiking of the IS solution. Afterwards, this mixture was again subjected to SPE prior to injection onto 
the chromatographic system.       
2.5 Instrumentation 
Chromatographic separation was achieved on an Acquity UPLC system (Waters, Milford, MA) 
equipped with an Acquity BEH C18 column (50 mm x 2.1 mm, 1.7 µm particle size) and an Acquity BEH 
C18 guard-column (5 mm x 2.1 mm, 1.7 µm particle size) all from Waters (Milford, MA). The column 
was kept at 50 °C. An aliquot of 1 µl was injected into the mobile phase stream using full loop 
injection. The mobile phases consisted of H2O (MPA) and methanol (MPB). Components were eluted 
using gradient elution at a flow rate of 0.450 ml/min. From 0 to 0.5 min the mobile phase contained 
55% of MPA. From 0.5 to 1.5 min the amount of MPB in the mobile phase was increased linearly to 
100%. Between 1.5 and 2.5 min, the system was maintained at 100% MPB. Finally, at 2.5 min, the 
analytical column was re-equilibrated to initial gradient settings. Eluting compounds were detected 
using a Waters Quattro Ultima triple quadrupole system (Micromass Waters, Manchester, UK) 
equipped with an electrospray source (orthogonal Z-spray®) operated in positive ionization (ESI+) 
mode. The MS/MS instrument was operated with a capillary voltage of 3.0 kV, source block 
temperature of 150 °C and cone voltage of 20 V. Nitrogen was used as desolvation gas and was 
heated to 400 °C and delivered to the source at 750 L/h. The system uses argon gas to induce 
fragmentation in the collision cell at a collision energy of 20 eV. The dwell time for each MRM 
transition was 100 ms and the interchannel and interscan delays were set to 20 ms. Details of the 
MRM-transitions for each compound are described in Table 1. Peak areas were integrated using 
MassLynx 4.1 software (Micromass Waters, Manchester, UK). 
2.6 Validation 
The validation experiments were based on the “Guidance for Industry-Bioanalytical Method 
Validation” recommended by the Food and Drug Administration (FDA) of the United States. Batches 
of quality control samples at three different concentration levels were prepared and analysed on 
separate occasions.  
2.6.1 Accuracy and imprecision 
Accuracy was evaluated by analysing results from QC samples measured under repeatability 
conditions on different days (QC samples were analysed in sextuplicate, triplicate or duplicate on 5 
different days). It was calculated as the mean relative error of QC samples analysed on five different 
days. Within-run imprecision was calculated as the average relative standard deviation (RSD) of the 
concentration of the QC samples. Between-run imprecision was evaluated by replicate 
measurements of QC samples on five different days. Between-run imprecision was calculated as the 
RSD of the average QC concentrations measured on five different days. 
2.6.2 Selectivity 
Selectivity was assessed by examining peak interference (signal-to-noise ratio < 9) from four 
independent sources of blank bovine muscle tissue. 
2.6.3 Stability 
The stability of PTX in tissue, stored at -80°C was assessed using bovine muscle controls. On day 0, 
blank bovine muscle tissue was homogenized and PTX working solutions were spiked to achieve PTX 
concentrations at the respective concentrations of the QC samples. Using fresh calibrator samples 
PTX concentrations in bovine muscle tissue were quantified on day 0 and after 1 month of storage at 
-80°C. The measured concentrations (measured in sextuplicate on three different concentration 
levels) were then used in a two-way ANOVA analysis in R®(R foundation for statistical computing, 
Vienna, Austria) to test whether significant degradation had occurred during this 1 month period.      
2.6.4 Robustness evaluation 
To further explore the performance characteristics of the developed method with tumour tissue 
samples rather than bovine muscle tissue quality control samples, tumour tissue samples for which a 
duplicate sample was available (n=20) were analysed 1 month after the original analysis.  
3 Results and discussion 
3.1 Method development 
3.1.1 Mechanical tissue homogenization 
Based on the work by Eckert et al.[11] we explored, as an initial sample preparation method, 
mechanical tissue homogenization using an Ultra-Turrax® (IKA®-Werke GmbH & Co. KG, Staufen, 
Germany) homogenizer in combination with a Potter-Elvehjem system (VWR Internation, Leuven, 
Belgium). The combination of both techniques, rather than only using an Ultra-Turrax®, is believed to 
produce a more complete cell disruption, making PTX bound to cell organelles freely available for 
extraction using SPE. Before homogenization a 6% phosphoric acid solution was added in a 1:1 (v/v) 
ratio to disrupt PTX protein binding. After centrifugation at 10,000 xg for 20 min the supernatant was 
subjected to SPE. 
 Based on the method described by Matuszewski et al.[12], we assessed the performance of 
the sample preparation technique, in terms of recovery and matrix effect, using bovine muscle 
quality control samples at three different PTX concentration levels (0.2, 0.4 and 2.0 ng/mg). 
Measurements of pre- / post- and pure standards were made in triplicate. As shown in Table 2, the 
average recovery was low (69.1 %). Furthermore, significant ion suppression was observed (average 
matrix effect 30.8 %). 
 Based on the strong protein binding affinity of PTX[13] and in an attempt to improve 
recovery and reduce the ion suppression, we decided to introduce an additional protein precipitation 
step prior to SPE. To this end, the 6% phosphoric acid solution was replaced by a 1:1 (v/v) mixture of 
0.06 N Ba(OH)2 and 0.06 N ZnSO4 (both Sigma-Aldrich, Bornem, Belgium). The average recovery and 
matrix effect of this improved sample preparation method were 96.8 % and 160.3 %, respectively. 
Although the average recovery was significantly better than the earlier method we were not satisfied 
with the results from this sample preparation method.  
On one hand the average matrix effect being significantly larger than 100 % (i.e. significant ion 
enhancement) and on the other hand the laborious procedure of mechanically processing the tissue 
with two separate techniques and the difficulties we faced, in terms of instrument 
maintenance/cleaning, when trying to mechanically homogenize low weight (± 25 mg tumour tissue) 
samples, in a high-throughput fashion, made us reconsider our approach. Although mechanical tissue 
homogenization has proven to be reliable in e.g. the accurate quantification of brain PTX 
concentrations[9], in our application, given the vast heterogeneity in tumour tissue composition and 
tumour tissue density it was regarded impracticable. For example, several of the tumours we 
encountered contained a high degree of dense fibrous-tissue, making it impossible, using mechanical 
techniques, to homogenize the tumour to a satisfactory degree (i.e. appearing like a homogeneous 
suspension).  
Therefore, based on a publication by Yu et al. [14], we explored enzymatic tissue digestion as an 
alternative sample preparation technique.  
 3.1.2 Enzymatic tissue digestion 
The enzymatic digestion described by Yu et al. [14] was based on two different enzymes (collagenase 
or proteinase K) that are known to degrade connective tissue. Apart from these two enzymes, other 
enzymes, e.g. subtilisin A [15], capable of digesting tissue samples have been described in literature. 
However, proteinase K, which is known to break up the cell nucleus (hence its widespread use in DNA 
extraction [16] protocols), in our opinion, since PTX resides, bound to the microtubules, inside the 
cell’s nucleus, would provide a more complete release of tissue bound PTX.  
Furthermore, in order to get rid of fatty residues from the tumour tissue which could disturb 
the SPE clean-up, we found it feasible to add lipase to the enzymatic digestion protocol. In literature, 
lipase has been used as an add-on enzyme in digestive protocols for the analysis of trace elements 
[17] as well as small-molecules [18] from a.o. human tissue samples.  
Based on these reports in literature, in a first step, we studied the effect of different 
concentrations of proteinase K (0.5, 1.0 and 5.0 units/mL) and lipase (100, 200 and 1000 mg/L) on 
the degree of digestion of tissue samples after an overnight incubation (approximately 16 hours) at 
55°C. 
 After centrifugation of the Eppendorf® vials, containing the incubated tissue samples, to 
precipitate any leftover solid particles, no residual solid pellet was observed for the highest 
proteinase K concentration (5.0 units/mL). Furthermore, by weighing of the residual pellet, obtained 
at the lower proteinase K concentrations, we found that the different lipase concentrations did not 
affect the degree of tissue digestion. Furthermore, using post column infusion of a PTX solution 
whilst injecting SPE extracts of bovine muscle tissue treated according to the different protocols, a 
qualitative assessment was made of the matrix effect. These results (data not shown) revealed that 
the most stable baseline following injection of the tissue sample extracts was obtained from the 
protocol with the highest proteinase K solution. However, no effect was observed for the different 
lipase concentrations tested. Therefore, it was decided to include lipase in the lowest concentration 
tested (i.e. 100 mg/L).  
 In an attempt to compare this enzymatic tissue digestion protocol with the earlier evaluated 
mechanical tissue homogenization techniques, the Matuszewski [12] experiments were repeated 
using the final digestive protocol described under 2.4. From Table 2 it is observed that neither the 
average recovery, nor the average matrix effect differs significantly from the theoretical optimal 100 
% value, making the enzymatic tissue digestion the best sample preparation amongst the ones 
compared in our study. Moreover, albeit the fact that it takes overnight to perform the digestion, this 
protocol requires very limited operator involvement, whereas the mechanical disruption based 
approaches are, indeed, faster but highly labour intensive. 
 As mentioned by Yu et al. [14], analyte instability should be considered and assessed when 
using an enzyme based digestive protocol. Therefore, we performed a stability study by comparing 
the PTX response in samples where PTX and IS were added prior to and after enzymatic tissue 
digestion (n=6 in all groups). In short, PTX and IS were added to (i) blank bovine muscle tissue prior to 
digestion or (ii) digested blank bovine muscle tissue, at a final concentration of 2000 ng/g. As shown 
in Figure 2, PTX as well as the IS undergo mild degradation during enzymatic digestion. The half-life 
of degradation, calculated from the estimated slopes (as the reciprocal of log10(2) and the estimated 
slope, on a log10-scale) of the solid and dashed lines, are 57.4 h and 58.7 h, respectively. From these 
estimated half-lives we calculated that during our 16 h incubation period approximately 17.6 % and 
17.2 % of PTX and IS will be degraded. From a sensitivity perspective, this is definitely acceptable, 
moreover, given that PTX and the IS are degraded to the same extent, this degradation will have no 
influence on the quantification, since the latter is based on the ratio of peak areas from PTX and IS.  
 Although, in general, in order to correct for variability during enzymatic digestion, one would 
choose to add the IS prior to the digestion, we choose to add it post digestion and prior to the SPE 
procedure. This way, samples above ULOQ could easily be diluted post digestion with a physiological 
saline solution, without having to use an IS supplemented dilution medium. 
3.2 Validation 
3.2.1 Accuracy and (intermediate) imprecision 
As seen from Table 3, bias and imprecision were within specifications dictated by the EMA guidance 
on bioanalytical method validation[19]. Since bias and imprecision for the lowest QC level were < 
20%, this level was accepted as LLOQ. Based on these results, our method proved to be precise and 
accurate.    
3.2.2 Selectivity 
No interferences were observed at the retention time of PTX and the IS when analysing blank bovine 
muscle tissue from 4 independent sources (data not shown). 
3.2.3 Stability 
Figure 3 depicts the measured QC concentrations (in sextuplicate) at day 0 and 1 month after the 
start of the stability experiment. From the graph it is seen that no significant degradation has 
occurred during storage at -80°C for 1 month. Moreover, a formal statistical significance test, using a 
two-factor ANOVA analysis to test the null hypothesis of no degradation, revealed a p-value (0.507) 
well in excess of the 0.05 level of significance cut-off, indicating that in our data, no evidence is 
present in favour of significant degradation.     
3.2.4 Robustness evaluation 
The results from the original analysis and the reanalysis (1 month after the original analysis) of a 
subset of tumour tissue samples is shown in Figure 4. Results for samples that were below the lower 
limit of quantification (BLOQ) (n= 8 in original and reanalysis) are not depicted on this figure.  When 
comparing the results from both analyses, it stands out that for some samples the results were 
similar, whereas for other samples results differed significantly between both analyses. (This is 
observed from the high degree of variability in the slopes of the solid lines in Figure 4). We calculated 
that only in 6/12 cases (without taking into account the measurements that were BLOQ), results 
were within -46.9% and 49.9% of their average value, indicating a high degree of variability between 
the results of both analyses.  
 Although our method proves to be accurate and precise, based on the validation data in 
bovine muscle quality control samples, the robustness experiment indicates that some aspect of the 
analysis is beyond our control. In our tumour tissue harvesting protocol (Figure 1) tumours roughly 
weighing a few hundred mg are partitioned in smaller subsections weighing approximately 50 mg. 
One part of this tumour tissue sample was used in the original analysis (25 mg), whilst the other part 
was used one month later in the reanalysis. To our opinion, due to the heterogeneous distribution of 
PTX, characterized by an exponential decrease in PTX concentrations as a function of penetration 
depth (Figure 5) within the tumour tissue, we were unable to collect tumour tissue samples that 
were similar in PTX concentrations, hence explaining the high variability observed.      
Apart from considering these results as a way of quantifying measurement uncertainty, one 
could consider this experiment as an extension to our earlier conducted stability study. For the 
robustness experiment, tumour tissue samples which contained PTX were stored for 1 month at -
80°C and therefore provide complementary information with regards to PTX stability. To test 
whether significant degradation had occurred in tumour tissue during storage, we used a paired 
sample t-test at the 5% level of significance. The resulting p-value of 0.679 indicates that no evidence 
is found in favour of significant degradation, which is in agreement with our earlier findings in bovine 
muscle tissue.    
         
3.3 Intratumoural distribution of PTX post IPEC dosing  
As a proof of concept for our developed methodology, Figure 5 provides details with regards to the 
analysis of tumour tissue samples harvested in an in-vivo experimental animal protocol described 
elsewhere[20]. In short, animals were treated with PTX by IPEC administration of Taxol®, and 
afterwards, tumours were harvested at different times post IPEC administration. PTX concentrations 
were determined for > 100 tumour tissue samples, using our developed method. The results from 
these analyses confirmed the suitability of our proposed methodology to address the question 
regarding the degree of and variability in tumour penetration of PTX post IPEC administration.  
The full pharmacokinetic results from this study are beyond the scope of this publication and 
are reported in detail elsewhere[20]. However, using the developed PKPD model, it was estimated 
that the half-width (similar to the half-live in plasma pharmacokinetics) of PTX tumour penetration 
was 1.37mm. This means that, for every 1.37 mm increment from the tumour’s surface towards the 
tumour’s centre, the PTX concentration was reduced with 50%. In other words, coming back to our 
hypothesis with regards to the high degree of variability observed in our robustness experiment, 
tumour tissue samples collected only 0.5 mm apart (with respect to the tumour’s centre) will, on 
average, show a 22.3 % difference in PTX concentration due to the exponential penetration profile.  
To our opinion, this explains why our robustness experiment showed such high variability 
between results from both analyses. Moreover, these results show that the pre-analytical phase, in 
this application, has a significant impact on the robustness of the analytical methodology and that 
the way forward, in this type of applications where the focus is on studying tissue penetration, is to 
further miniaturize the sample collection protocol.       
     
 4. Conclusion 
This study presents the development and validation of an assay to be used in the determination of 
PTX in tumour tissue samples. Sufficient evidence is provided to gain insights in the performance of 
the developed method. Nevertheless, future efforts should be directed to improve the robustness of 
the methodology with respect to PTX determinations in tumour tissue samples originating from in-
vivo experiments. To our opinion, the pre-analytical phase, consisting of the harvesting and 
subsectioning of the tumours holds room for improvement. One way of addressing this problem, is to 
our opinion, the further minimization of the harvested tumour samples so that samples that are 
harvested in close proximity to each other show less variable tissue composition and PTX 
concentrations.    
Through the use of an enzymatic tissue digestion protocol, we minimized matrix effects whilst 
simultaneously maximizing recovery. Furthermore, sample handling was minimized as compared to 
the mechanical homogenization, providing the analyst with an easy, less labour intensive, sample 
preparation protocol. Finally, using automatic pipettes and/or robotic based instrumentation this 
sample preparation could easily be adapted to accommodate sample preparation in a high-
throughput fashion.    
 As a concluding proof-of-concept, we used our enzymatic tissue digestion protocol to analyse 
samples from an experimental animal trial with rats being administered PTX through IPEC.  
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Figure and Table Captions 
Table 1 
Detection parameters for the compounds under study. 
Table 2 
Recovery and Matrix effect for the different sample preparation protocols under study. 
Table 3 
Results for the validation experiments based on bovine muscle tissue quality control samples. 
Figure 1 
Tumour harvesting protocol. 
Figure 2 
PTX and IS stability during enzymatic tissue digestion. The black symbols represent the measured 
peak areas for PTX, whereas the grey symbols denote the peak areas as a function of time for the IS. 
All 18 samples were analysed in a single run. The solid and dashed line are the predicted peak areas , 
according to a linear model treating time as a continuous covariate, for PTX and the IS, respectively. 
From the model estimated slopes it was estimated that the half-live for degradation for PTX and the 
IS were 57.4 h and 58.7 h, respectively.    
Figure 3 
The measured PTX concentrations at day 0 and 1 month after the start of the stability experiment. 
Spiked bovine muscle QC samples were stored for 1 month at -80°C prior to analysis. The p-value 
indicates that using a two-factor ANOVA analysis, at the 5% level of significance, no evidence was 
present in the data in favour of significant degradation.  
Figure 4 
Results from the robustness evaluation. The individually measured concentrations from “duplicate” 
samples are depicted by open circles and are joined together by a solid line. The p-value indicates 
that, using a paired sample t-test, no evidence is found in favour of significant degradation when 
tumour tissue is stored at -80°C. 
Figure 5 
The PTX penetration profile in tumour tissue post IPEC administration of 30mg of Taxol®. The circles 
represent measured PTX concentrations as a function of penetration depth, whereas the solid and 
dashed lines represent the mean predicted PTX tumour tissue concentration, based on our published 
PKPD model[20], as well as the 95% confidence interval on this prediction. 
 Table 1 
Detection parameters for the compounds under study. For the different compounds, a quantifier and qualifier trace were 
monitored. Qualifier traces were used to calculate ion ratios. These ion-ratios were monitored during the analysis to 
confirm the identity of the measured compound.  
 Detection MRM-transitions  CE 
Compound Ionisation mode Quantifier Qualifier (eV) 
PTX ESI + 876.5 > 307.5 876.5 > 531.0 20 
13C6-PTX ESI + 882.5 > 313.7 882.5 > 531.0 20 
 
 Table 2 
 Recovery Matrix effect 
 Average (%) SE (%) Average (%) SE (%) 
Mechanical homog. 69.1* 12.3 30.8* 1.6 
Mechanical + PP 96.8 5.8 160.3* 9.1 
Enzymatic digestion 118.4 9.8 110.0 9.0 
Measurements were made in triplicate on 3 different PTX concentration levels. The reported 
recoveries and matrix effects are the average over the replicates and different concentration levels. * 
indicates an average recovery or matrix effect being statistically significantly different from 100 % at 
the 5 % level of significance.  
 Table 3 
 Concentration Bias 
Within-run 
imprecision 
Between-run 
imprecision 
 (ng/g) (%) (%) (%) 
QC Low 80 10.7 17.2 7.9 
QC Medium 1600 7.3 5.0 13.6 
QC High 6400 7.9 6.3 11.8 
QC’s were analyzed on 5 different days. Analysis on day 1, day 2 and days 3,4 and 5 were carried out 
in sextuplicate, triplicate and duplicate, respectively. For QC low and QC medium 1 and 2 outliers 
were excluded, respectively.  
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